NeoModulus Completes Hundred-Million-Yuan Series A++ Financing to Advance Multiple Implantable Medical Device Pipelines

VCBeat has learned firsthand that recently, Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd. (hereinafter referred to as "Neo Modulus") announced the completion of a Series A++ financing round valued at over RMB 100 million. This round was led by the Westlake University Industry Investment Fund, with follow-on investments from existing investors including Huiding Investment, Su Gaoxin Venture Capital, One Zero Fund, Junmao Capital, Baofu Investment, and other institutions. The proceeds will be primarily used to further advance multiple implantable medical device pipelines in the tissue engineering field and to implement the company's internationalization strategy.

Since its establishment in March 2017, Neo Modulus has completed multiple financing rounds, with cumulative funding exceeding RMB 500 million. Among these, the company's RMB 150 million Series A+ financing was completed this year, led by CDH VGC (CDH Innovation & Growth Fund).

Co-founded by a management and technical team from China and Germany, Neo Modulus is an innovative enterprise dedicated to the R&D and manufacturing of implantable medical devices “that enable human tissue repair and organ regeneration.” The company has been recognized on the potential unicorn and unicorn incubation enterprise lists at the national, provincial, municipal, and district levels. Taking “regenerative implantable medical devices” as its core focus, Neo Modulus implements a development strategy of “multiple technologies, diverse product lines, and multiple market tracks,” and has established over a dozen product pipelines covering clinical specialties such as dentistry, ophthalmology, otorhinolaryngology, surgery, medical aesthetics, reproductive medicine, and sports medicine.

Neo Modulus operates two major domestic R&D and production bases and an overseas laboratory in Freiburg, Germany. Its products under development encompass multiple mainstream technological routes in the global tissue engineering field, including 3D electrospinning, conventional electrospinning, 3D bioprinting, chemical synthesis, and physical synthesis. The portfolio spans various product formats such as membranes, bone grafts, hydrogels, formulations, and (micro)spheres. By effectively addressing critical challenges ("pain points") in tissue regeneration, wound repair, and functional reconstruction—including periodontal soft tissue augmentation, cartilage and bone tissue regeneration, and craniomaxillofacial repair—Neo Modulus stands as one of the comprehensive solution providers in China's tissue engineering sector, distinguished by a complete technological portfolio and advanced capabilities.

Since the beginning of 2021, Neo Modulus has accelerated the industrialization of multiple product pipelines: its Suzhou headquarters has completed patient enrollment for the clinical trials of the first core product, while clinical trials for other core products are also being accelerated; a joint venture has been established with the Shanghai Institute of Ceramics, Chinese Academy of Sciences to accelerate the translation of a series of 3D-printed biomaterial products; and its Shandong facility has completed the topping-out of the first standalone cleanroom building, with pilot-scale production already completed for multiple core products.

Regarding this round of financing, Neo Modulus Co-founder, Chairman and General Manager Zhang WencaiStated: I would like to express my sincere gratitude to the Westlake University Industry Investment Fund and all investing institutions for your recognition and support. The founding scientific team of Neo Modulus hails from China and Germany. From its inception, the company has been imbued with an international DNA, continuously focusing on and tackling the critical challenges and technical bottlenecks in the global field of tissue engineering. Neo Modulus is strategically positioned as a "focused and specialized, hard-tech, and globally oriented" enterprise. I am confident that the infusion of new capital will undoubtedly accelerate our development pace and propel Neo Modulus toward becoming an internationally influential hard-tech company.

Zhang Fan, General Manager, Westlake University (Hangzhou) Equity Investment Co., Ltd.Stated: Neo Modulus is a leading enterprise in the field of tissue engineering and regenerative medicine, with its management and technical teams possessing robust innovation capabilities and extensive industrialization experience. As China's first new-type research university established by social forces and backed by key national support, Westlake University is dedicated to making outstanding contributions to basic scientific research, original technological innovation, and the translation of scientific and technological achievements. The Westlake University Industry Investment Fund has consistently focused on technological innovation and the commercialization of research outcomes. We are confident that Neo Modulus will deepen its strategic presence in the implantable medical device sector, thereby creating greater social value for China's life and health industry.